

FIG. 1A




FIG. 1B





FIG. 2



	D arm	PBO arm
No. events / no. patients (%)	98/366 (26.8)	138/374 (36.9)
mEFS, months (95% CI)	NR (31.9–NR)	25.9 (18.9–NR)
Stratified HR* (95% CI)	0.68 (0.53–0.88)	
Stratified log-rank <i>P</i> -value	0.003902	

Median follow-up (range) in censored patients: 11.7 months (0.0–46.1)

EFS maturity: 31.9%



FIG. 3

FIG. 4A



6/14
FIG. 4B





FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 4G





FIG. 5



P-value = 0.000002
based on interim
analysis (n=402)†

P-value = 0.000036
based on interim
analysis (n=402)†

FIG. 6




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9




FIG. 10

